ARDX
ARDELYX, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.99
−9.12%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$3.26
From 52W high−62.58%
Volume7.74M
Market cap$751.60M
P/E (TTM)—
P/S (TTM)1.6x
Div yield—
Key dataNov 5, 2026
Open
$3.26
From 52W high
−62.58%
Volume
7.74M
Market cap
$751.60M
ValuationView details →
P/E (Fwd)
181.8x
EV/EBITDA
−25.2x
P/E (TTM)
—
RSI (14)
46.1
MomentumView details →
1D Return
−9.12%
YTD Return
−46.23%
SummaryUpdated Sep 1, 2026
Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company founded in 2007 and headquartered in Waltham, Massachusetts. Originally incorporated as Nteryx, Inc., the company changed its name to Ardelyx in June 2008 and went public in 2014. Ardelyx has evolved from a development-stage biotechnology company into a commercial-stage organization with two FDA-approved products addressing unmet medical needs in gastrointestinal and kidney-related conditions. The company has successfully transitioned from years of research and development losses to achieving profitability in 2024, marking a significant milestone in its corporate evolution.
Similar companies
Latest newsMore news →
ARDELYX, INC. reported break-even earnings per share for the third quarter, compared with a Zacks Investment Research, Inc. consensus estimate of a $0.03 loss and break-even earnings per share a year earlier.2d agoARDELYX, INC. reported $285.3 million in cash, cash equivalents and investments as of September 30, 2026.2d agoARDELYX, INC. reported third-quarter 2026 total product revenue of $125.5 million, up 19% year over year, including IBSRELA revenue of $96.3 million, up 23%.2d ago